Search clinical trials for: intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine nab-paclitaxel

Total 132 results

Fudan University

Recruiting

DDP ip Combined With AG in PDAC With Peritoneal Metastasis

Pancreatic Neoplasm

China
Hutchmed

Recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Yang Jianjun, PhD

Not yet recruiting

Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Pancreatic Cancer Action Network

Active, not recruiting

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Phase I Dose-finding Trial of Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin

Ovarian Cancer | Paclitaxel | Hyperthermic Intraperitoneal Chemotherapy

China
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine Chemotherapy for Pancreatic Cancer Peritoneal Metastases (Nab-PIPAC)

Peritoneal Carcinomatosis | Pancreas Neoplasm

Italy
Changhai Hospital

Recruiting

Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1 (BRPCNCC-1)

Pancreatic Cancer

China
Wuhan Union Hospital, China

Not yet recruiting

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma, PDAC

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

China
Fudan University

Unknown

Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fudan University

Recruiting

Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma (INSIGHT)

Laryngeal Cancer | Laryngeal Neoplasms | Hypopharynx Cancer

China
AHS Cancer Control Alberta
Celgene

Active, not recruiting

A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer (AX-CSARC)

Unresectable Biliary Tract Cancer

Canada
Women's Hospital School Of Medicine Zhejiang University
Sun Yat-sen University; Qilu Hospital of Shandong University; Second Affiliated... and other collaborators

Recruiting

Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

Epithelial Ovarian Carcinoma Stage III | Epithelial Ovarian Carcinoma Stage IV | Fallopian Tube Carcinoma Stage III | Fallopian Tube Carcinoma Stage IV | Primary Peritoneal Carcinoma Stage III | Primary Peritoneal Carcinoma Stage IV

China
Tata Memorial Centre

Recruiting

Radiation Therapy in Unresectable Gall Bladder Cancer (RUGB)

Gall Bladder Cancer

India
Fudan University

Completed

ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC

Non Small Cell Lung Cancer

China
Fifth Affiliated Hospital, Sun Yat-Sen University

Recruiting

Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
UNC Lineberger Comprehensive Cancer Center

Terminated

Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC (LCCC1407)

Stage IIIA Non-Small Cell Lung Cancer

United States
Huazhong University of Science and Technology
CSPC Ouyi Pharmaceutical Co., Ltd.

Unknown

A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer

Biliary Tract Cancer

China
IRCCS San Raffaele

Completed

A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma (PACT-19)

Pancreatic Cancer

Italy
University of Texas Southwestern Medical Center
BerGenBio ASA; Translational Genomics Research Institute; Triligent International

Terminated

Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer

Cancer of Pancreas

United States
CHA University
Dong-A Pharmaceutical

Recruiting

Biomarker Discovery in Patients With Advanced Biliary Tract Cancer

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

Korea, Republic of
Yang Jianjun, PhD

Recruiting

Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer

Advanced Gastric Cancer

China
West China Hospital

Not yet recruiting

Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer

Gastric Cancer
Shanghai Zhongshan Hospital

Not yet recruiting

Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage Ⅲ Gastric Cancer

Gastric Cancer
Atlantic Health System
Cornerstone Pharmaceuticals

Unknown

A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer | Metastatic Pancreatic Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Chinese PLA General Hospital

Completed

Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract

Carcinoma, Transitional Cell

China
Pancreatic Cancer Research Team
Celgene

Withdrawn

Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients

Resectable Pancreatic Cancer
Fudan University

Not yet recruiting

Phase II Study of Sufantinib Combined With AG Versus AG First-line in the Treatment of LAPC or mPC

Pancreatic Neoplasms

China
Sun Jing

Not yet recruiting

A Clinical Study on the Efficacy and Safety of Paclitaxel Polymer Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Locally Advanced Esophageal Squamous Cell Carcinoma
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

Solid Tumor

China
Pancreatic Cancer Research Team
Translational Genomics Research Institute; Cancer Research and Biostatistics... and other collaborators

Completed

Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA

Stage IV Pancreatic Cancer

United States
Eli Lilly and Company

Active, not recruiting

A Study of LY3200882 in Participants With Solid Tumors

Solid Tumor

United States, Spain, Japan, France, Italy, Australia, Germany, Canada
Gruppo Oncologico del Nord-Ovest

Recruiting

CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence (PURITY)

Cholangiocarcinoma | Biliary Tract Cancer

Italy
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Celgene

Active, not recruiting

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Resectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8

United States
Guizhou Medical University

Unknown

Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC

Efficacy and Safety

China
Jianjun Yang
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer

Gastric Cancer

China
Samsung Medical Center

Withdrawn

A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea

Intrahepatic Cholangiocarcinoma
IRCCS San Raffaele

Recruiting

PAXG Out in the Country (OINC)

Pancreatic Ductal Adenocarcinoma

Italy
Verastem, Inc.

Recruiting

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (RAMP205)

Metastatic Cancer | Pancreas Cancer | Neoplasms Pancreatic | KRAS Activating Mutation | Malignant Neoplasm of Pancreas

United States
HonorHealth Research Institute
Celgene

Active, not recruiting

Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

United States
Zhejiang Cancer Hospital

Recruiting

Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites

Gastric Cancer | Peritoneal Metastases | Ascites, Malignant

China
Sichuan Cancer Hospital and Research Institute

Unknown

Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer

Lung Cancer

China
Shanghai Zhongshan Hospital

Unknown

Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic
Peking University Cancer Hospital & Institute

Recruiting

Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

Gastric Adenocarcinoma

China
Lyudmyla Berim

Active, not recruiting

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Non Small Cell Lung Cancer

China
Jiangsu Healthy Life Innovation Medical Technology...

Not yet recruiting

Clinical Study of Tumor Treating Fields Combined With Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Pancreatic Carcinoma | Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma

United States
Zhejiang Cancer Hospital

Unknown

Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma Resectable

China

Search clinical trials for: intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine nab-paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations